Stay updated with breaking news from Sponsored Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CARSON CITY, Nev., Dec. 06, 2022 -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced... | December 6, 2022
- Investigator Sponsored Trial sites in Australia include St. Vincent's Hospital, Sydney, Alfred Health, Melbourne, and the Royal Victorian Eye and Ear...
. The rESPECT IST (NCT04292743) is a single arm, dose escalating Phase 1 clinical trial to evaluate the safety of eryaspase in combination with modified FOLFIRINOX. The trial is conducted by Dr Marcus Noel, Associate Professor of Medicine at Georgetown University, Washington DC, USA, and will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer. FOLFIRINOX is one of the most commonly utilized first-line chemotherapy regimens for the treatment of pancreatic cancer, despite its toxicity. The trial was laun...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ... Erytech Pharma S.A.April 19, 2021 GMT ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer No dose-limiting toxicity reported in the first dose cohort Encouraging clinical activity observed in first patients Trial will be escalated to the next dose Lyon (France) and Cambridge, MA (U.S.), April 19, 2021 – ERYTECH Pharma (Nasd...